- Home
- WHF vs ACHV Comparison
WHF vs ACHV Comparison
Compare WHF & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- ACHV
- Stock Information
- Founded
- WHF 2011
- ACHV N/A
- Country
- WHF United States
- ACHV United States
- Employees
- WHF N/A
- ACHV N/A
- Industry
- WHF Finance Companies
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- WHF Finance
- ACHV Health Care
- Exchange
- WHF Nasdaq
- ACHV Nasdaq
- Market Cap
- WHF 162.2M
- ACHV 167.6M
- IPO Year
- WHF 2012
- ACHV N/A
- Fundamental
- Price
- WHF $7.09
- ACHV $4.97
- Analyst Decision
- WHF Hold
- ACHV Strong Buy
- Analyst Count
- WHF 4
- ACHV 1
- Target Price
- WHF $9.17
- ACHV $12.00
- AVG Volume (30 Days)
- WHF 153.0K
- ACHV 2.3M
- Earning Date
- WHF 11-10-2025
- ACHV 11-07-2025
- Dividend Yield
- WHF 25.36%
- ACHV N/A
- EPS Growth
- WHF N/A
- ACHV N/A
- EPS
- WHF 0.15
- ACHV N/A
- Revenue
- WHF $81,499,000.00
- ACHV N/A
- Revenue This Year
- WHF N/A
- ACHV N/A
- Revenue Next Year
- WHF N/A
- ACHV N/A
- P/E Ratio
- WHF $46.00
- ACHV N/A
- Revenue Growth
- WHF N/A
- ACHV N/A
- 52 Week Low
- WHF $6.53
- ACHV $1.84
- 52 Week High
- WHF $12.18
- ACHV $5.78
- Technical
- Relative Strength Index (RSI)
- WHF 44.48
- ACHV 75.92
- Support Level
- WHF $6.96
- ACHV $4.72
- Resistance Level
- WHF $7.20
- ACHV $5.78
- Average True Range (ATR)
- WHF 0.21
- ACHV 0.33
- MACD
- WHF 0.09
- ACHV 0.16
- Stochastic Oscillator
- WHF 76.39
- ACHV 71.46
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.